Gilead shares sink as the FDA rejects the company’s arthritis drug
5 years ago 1 min read
A look at Gilead, which sank after its arthritis drug was rejected by the FDA. With CNBC’s Brian Sullivan and the Fast Money traders, Guy Adami, Tim Seymour, Bonawyn Eison and Dan Nathan.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push